MedTrace Logo

Effect of Metformin on Frailty in 12 Subjects

NCT03451006 · Status: TERMINATED · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 7

Last updated 2022-11-17

Study results available
· View outcomes & findings →

Summary

This study will test whether chronic metformin administration will improve longevity of the cell, improves its machinery by reducing aging-related biochemical parameters and thereby improving physical performance, as measured by short physical performance battery test.

Conditions

Interventions

DRUG

Metformin

Oral metformin (up to 2gm) will be given in divided doses

DRUG

Placebo

Oral Placebo will be given in divided doses

Sponsors & Collaborators

Principal Investigators

  • Mandeep Singh · Mayo Clinic

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
DOUBLE
Model
PARALLEL

Eligibility

Min Age
60 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2018-05-24
Primary Completion
2021-12-16
Completion
2021-12-16
FDA Drug
Yes

Countries

  • United States

Study Locations

More Related Trials

Entities

Drugs
Diseases
Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT03451006 on ClinicalTrials.gov